| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 08/09/2023 | Rain Oncology Inc. | RAIN | Grant | Stock Option (Right to Buy) | 35k | $1.21 | $42.4k | | 08/09/2023 |
| 06/15/2023 | Kezar Life Sciences, Inc. | KZR | Grant | Stock Option (right to buy) | 35k | $2.64 | $92.4k | | 06/15/2023 |
| 06/13/2023 | Atreca, Inc. | BCEL | Grant | Stock Option (right to buy) | 12k | $1.18 | $14.2k | | 06/13/2023 |
| 12/21/2022 | ESSA Pharma Inc. | EPIX | Sale | Common Shares | 34.3k | $2.42 | $83.1k | | 12/14/2022 |
| 12/21/2022 | ESSA Pharma Inc. | EPIX | Sale | Common Shares | 37.9k | $2.41 | $91.3k | | 12/14/2022 |
| 12/20/2022 | ESSA Pharma Inc. | EPIX | Sale | Common Shares | 43.6k | $2.53 | $110.4k | | 12/14/2022 |
| 12/16/2022 | ESSA Pharma Inc. | EPIX | Sale | Common Shares | 50k | $2.67 | $133.5k | | 12/14/2022 |
| 12/15/2022 | ESSA Pharma Inc. | EPIX | Sale | Common Shares | 32k | $2.90 | $92.8k | | 12/14/2022 |
| 12/15/2022 | ESSA Pharma Inc. | EPIX | Sale | Common Shares | 50k | $2.86 | $143k | | 12/14/2022 |
| 12/14/2022 | ESSA Pharma Inc. | EPIX | Sale | Common Shares | 25k | $3.00 | $75k | | 12/14/2022 |
| 11/22/2022 | Rain Oncology Inc. | RAIN | Purchase | Common Stock | 77k | $8.27 | $636.8k | | 11/21/2022 |
| 11/21/2022 | Rain Oncology Inc. | RAIN | Purchase | Common Stock | 45k | $7.80 | $351k | | 11/21/2022 |
| 11/14/2022 | Atea Pharmaceuticals, Inc. | AVIR | Sale | Common Stock | 16.2k | $5.16 | $83.4k | | 11/11/2022 |
| 11/11/2022 | Atea Pharmaceuticals, Inc. | AVIR | Sale | Common Stock | 25.5k | $5.15 | $131.3k | | 11/11/2022 |
| 11/08/2022 | Rain Oncology Inc. | RAIN | Purchase | Common Stock | 42.9k | $5.83 | $250k | | 11/08/2022 |
| 06/29/2022 | ESSA Pharma Inc. | EPIX | Grant | Stock Option (Right to Buy) | 22.5k | $3.60 | $81k | | 06/29/2022 |
| 06/17/2022 | Atea Pharmaceuticals, Inc. | AVIR | Grant | Stock Option (Right to Buy) | 61.3k | $6.50 | $398.2k | | 06/17/2022 |
| 06/16/2022 | Kezar Life Sciences, Inc. | KZR | Grant | Stock Option (right to buy) | 26k | $4.80 | $124.8k | | 06/16/2022 |
| 06/08/2022 | Atreca, Inc. | BCEL | Grant | Stock Option (right to buy) | 12k | $2.09 | $25.1k | | 06/08/2022 |
| 06/01/2022 | Rain Oncology Inc. | RAIN | Grant | Stock Option (Right to Buy) | 20k | $2.44 | $48.8k | | 06/01/2022 |
| 03/21/2022 | Kezar Life Sciences, Inc. | KZR | Purchase | Common Stock | 20k | $14.77 | $295.4k | | 03/18/2022 |
| 03/18/2022 | Kezar Life Sciences, Inc. | KZR | Purchase | Common Stock | 15k | $15.96 | $239.4k | | 03/18/2022 |
| 03/18/2022 | Kezar Life Sciences, Inc. | KZR | Purchase | Common Stock | 45k | $17.00 | $765k | | 03/18/2022 |
| 09/22/2021 | Kezar Life Sciences, Inc. | KZR | Exercise | Stock Option (Right to Buy) | 8.9k | $5.60 | $49.8k | | 09/21/2021 |
| 09/21/2021 | Kezar Life Sciences, Inc. | KZR | Exercise | Stock Option (Right to Buy) | 8.9k | $5.91 | $52.6k | | 09/21/2021 |
| 09/21/2021 | Kezar Life Sciences, Inc. | KZR | Exercise | Stock Option (Right to Buy) | 8.9k | $7.63 | $67.9k | | 09/21/2021 |
| 09/21/2021 | Rain Oncology Inc. | RAIN | Purchase | Common Stock | 3.8k | $14.30 | $54.1k | | 09/21/2021 |
| 06/28/2021 | Kezar Life Sciences, Inc. | KZR | Grant | Stock Option (Right to Buy) | 26k | $5.59 | $145.3k | | 06/28/2021 |
| 06/18/2021 | Atea Pharmaceuticals, Inc. | AVIR | Grant | Stock Option (Right to Buy) | 34k | $23.39 | $795.8k | | 06/18/2021 |
| 06/09/2021 | Atreca, Inc. | BCEL | Grant | Stock Option (right to buy) | 12k | $10.27 | $123.2k | | 06/09/2021 |
| 05/14/2021 | Rain Oncology Inc. | RAIN | Grant | Stock Option (Right to Buy) | 24k | $15.33 | $367.9k | | 05/14/2021 |
| 04/27/2021 | Rain Oncology Inc. | RAIN | Conversion | Common Stock | 175.9k | $0.00 | $0 | | 04/23/2021 |
| 04/27/2021 | Rain Oncology Inc. | RAIN | Conversion | Common Stock | 535.6k | $0.00 | $0 | | 04/23/2021 |
| 04/27/2021 | Rain Oncology Inc. | RAIN | Conversion | Series A Preferred Stock | 190k | $0.00 | $0 | | 04/23/2021 |
| 04/27/2021 | Rain Oncology Inc. | RAIN | Conversion | Series B Preferred Stock | 578.4k | $0.00 | $0 | | 04/23/2021 |
|